-
Posted by
Two Blokes Jul 16 -
Filed in
Stock
-
1 view
Highest Rated Children's Medical Centers Now Employ QUELIMMUNE for Ultra-Rare Cases of Pediatric AKI HDE Surveillance Registry Data Captures Key Metrics for Future Analysis of QUELIMMUNE Performance DENVER, July 16, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company announced today that it has added a nationally-recognized, Texas-based children's hospital to its growing customer base of QUELIMMUNE therapy users. The QUELIMMUNE therapy was approved by the U.S. Food and Drug Administration in 2024 under a Humanitarian Device Exemption (HDE) to treat pediatric patients with life-threatening, ultra-rare Acute Kidney Injury (AKI) due to sepsis or a septic condition on antibiotic therapy and requiring Renal Replacement Therapy (RRT).
